GLSI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.0M
-29.8%
5.7M
-27.9%
7.9M
+90.3%
4.2M
+10.8%
3.8M
R&D
3.6M
-31.7%
5.2M
-31.4%
7.6M
+115.5%
3.5M
+3.1%
3.4M
SG&A
462.9K
-10.7%
518.2K
+45.9%
355.2K
-45.6%
653.1K
+85.1%
352.8K
Operating Income
-4021645
+29.8%
-5725754
+27.9%
-7944991
-90.3%
-4174642
-10.8%
-3769315
EBITDA
-4021645
+29.8%
-5725754
+27.9%
-7944991
-90.3%
-4174642
-10.7%
-3770218
Net Income
-3948675
+30.2%
-5657137
+28.6%
-7922733
-90.8%
-4151845
-10.8%
-3748640
EPS (Basic)
$-0.27
+30.8%
$-0.39
+31.6%
$-0.57
-90.0%
$-0.30
-7.1%
$-0.28
EPS (Diluted)
$-0.27
+30.8%
$-0.39
+31.6%
$-0.57
-90.0%
$-0.30
-7.1%
$-0.28
Shares (Diluted)
14.6M
+0.4%
14.6M
+4.4%
14.0M
+2.3%
13.6M
+2.0%
13.4M
Greenwich LifeSciences (GLSI) โ€” Financials